Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. The post Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. appeared first on Investor's Business Daily.
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths.
The post Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
